表观遗传调控细胞内在免疫反应拮抗急性髓系白血病自我更新
本研究揭示组蛋白去甲基化酶PHF8是急性髓系白血病细胞内在免疫反应的直接启动子和调控因子,其位点特异性磷酸化上调胞质RNA传感器(尤其是TRIM25-RIG-I-IFIT5轴),触发IFN-I反应-分化-凋亡网络,在体外和体内拮抗多种亚型人AML细胞的分化阻滞和生长。对超过200例原发AML骨髓样本的蛋白质组分析发现,半数患者存在独特的PHF8/IFN-I特征,且与已知临床或遗传学AML亚组无显著关联,该特征在健康CD34+造血祖细胞中缺失。
要点
- PHF8是AML细胞内在免疫反应的直接启动子和调控因子。
- PHF8磷酸化上调TRIM25-RIG-I-IFIT5轴,触发IFN-I反应-分化-凋亡网络。
- 半数原发AML患者存在PHF8/IFN-I特征,健康CD34+祖细胞中缺失。
核心结论
- PHF8作为组蛋白去甲基化酶,是AML细胞内在免疫反应的直接启动子和调控因子,其磷酸化触发的信号级联在体外和体内 largely 拮抗人AML细胞的分化阻滞和生长。
- 半数原发AML患者存在独特的PHF8/IFN-I特征,健康CD34+造血祖细胞中缺失,提示PHF8磷酸化的药理支持在大部分AML患者中具有治疗适用性。
研究设计与样本
- 研究对超过200例原发AML骨髓样本进行蛋白质组分析,并在体外和体内评估PHF8磷酸化对AML细胞生长的影响。
主要发现
- PHF8位点特异性磷酸化协调表观遗传变化,上调胞质RNA传感器,尤其是TRIM25-RIG-I-IFIT5轴,触发细胞IFN-I反应-分化-凋亡网络。
- 该信号级联在体外和体内 largely 拮抗多种疾病亚型人AML细胞的分化阻滞和生长。
- 超过200例原发AML骨髓样本蛋白质组分析中,半数患者群体存在独特的PHF8/IFN-I特征,与已知临床或遗传学定义的AML亚组无显著关联。
- 该特征在健康CD34+造血祖细胞中缺失。
- 药理支持PHF8磷酸化显著损害原发AML患者样本的生长。
关键数值与推荐
- 超过200例原发AML骨髓样本中,半数患者存在PHF8/IFN-I特征。
- 该特征与已知临床或遗传学定义的AML亚组无显著关联。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epigenetic modulation of the cell-intrinsic immune response holds promise as a therapeutic approach for leukemia. However, current strategies designed for transcriptional activation of endogenous transposons and subsequent interferon type-I (IFN-I) response, show limited clinical efficacy. Histone lysine methylation is an epigenetic signature in IFN-I response associated with suppression of IFN-I and IFN-stimulated genes, suggesting histone demethylation as key mechanism of reactivation. In this study, we unveil the histone demethylase PHF8 as a direct initiator and regulator of cell-intrinsic immune response in acute myeloid leukemia (AML). Site-specific phosphorylation of PHF8 orchestrates epigenetic changes that upregulate cytosolic RNA sensors, particularly the TRIM25-RIG-I-IFIT5 axis, thereby triggering the cellular IFN-I response-differentiation-apoptosis network. This signaling cascade largely counteracts differentiation block and growth of human AML cells across various disease subtypes in vitro and in vivo. Through proteome analysis of over 200 primary AML bone marrow samples, we identify a distinct PHF8/IFN-I signature in half of the patient population, without significant associations with known clinically or genetically defined AML subgroups. This profile was absent in healthy CD34+ hematopoietic progenitor cells, suggesting therapeutic applicability in a large fraction of patients with AML. Pharmacological support of PHF8 phosphorylation significantly impairs the growth in samples from patients with primary AML. These findings provide novel opportunities for harnessing the cell-intrinsic immune response in the development of immunotherapeutic strategies against AML.
引用
- Felipe Fumero E, Walter C, Frenz JM, et al. Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia. Blood. 2024. PMID: 38457355. doi:10.1182/blood.2023021640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。